

## Limited Submission Funding Opportunities – updated 12/31/20

*Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.*

*For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.*

*This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.*

*For further questions, please contact ECOR at [ecor@mgc.harvard.edu](mailto:ecor@mgc.harvard.edu)*

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgc.harvard.edu](mailto:ecor@mgc.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgc.harvard.edu](mailto:ecor@mgc.harvard.edu).

### CURRENT OPPORTUNITIES

#### 1. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-055.html>

**MGH LOI Deadline: 1/05/21**

NIH Application Deadline: 2/26/21

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research career development beyond their doctoral degrees. The objective of this award is to facilitate a timely

## Limited Submission Funding Opportunities – updated 12/31/20

transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this Funding Opportunity Announcement (FOA) include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA, [RFA-CA-20-056](#)

### 2. NCI Pathway to Independence Award for Outstanding for Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-056.html>

**MGH LOI Deadline: 1/05/21**

NIH Application Deadline: 2/26/21

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

*This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA ([RFA-CA-20-057](#)).*

### 3. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-057.html>

**MGH LOI Deadline: 1/05/21**

NIH Application Deadline: 2/26/21

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-

## Limited Submission Funding Opportunities – *updated 12/31/20*

supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ([RFA-CA-20-056](#)).

### 4. Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-030.html>

**MGH LOI Deadline: 1/12/21**

NIH LOI Deadline: 2/03/21

NIH Application Deadline: 3/03/21

Since its establishment in 2006, the Gastroparesis Clinical Research Consortium (GpCRC), a multi-center coalition created and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has made major advances to our understanding of the pathophysiology of Gastroparesis (Gp).

Through the establishment of the largest gastroparesis tissue repository in the United States, combined with detailed phenotypic data, the GpCRC is ideally suited to accelerate insights into the underlying cellular and molecular pathophysiology of the gastroparesis with the ultimate goal of developing therapeutic target(s).

This RFA invites investigators from several disciplines, including basic and translational research in areas of neurosciences, immunology, microbiology and physiology, to contribute new insights into the cellular and molecular mechanisms of Gastroparesis.

### 5. Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV – Coordinating Center – NEW!

<https://www.hrsa.gov/grants/find-funding/hrsa-21-076>

**MGH LOI Deadline: 2/01/21**

Sponsor Application Deadline: 3/08/21

This notice announces the opportunity to apply for fiscal year 2021 (FY21) Health Resources and Services Administration (HRSA) Special Projects of National Significance (SPNS) Program funding for the initiative *Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV – Coordinating Center*. The purpose of this initiative is to use an implementation science framework to identify innovative intervention strategies in four (4) focus areas, pilot test the intervention strategies at subawarded sites and provide technical assistance (TA), and develop replication tools and products. HRSA will provide funding in the form of a cooperative agreement to support one (1) organization for up to four (4) years to serve as the Innovative Intervention Strategies Coordinating Center for Technical

## Limited Submission Funding Opportunities – updated 12/31/20

Assistance (2iS CCTA). The 2iS CCTA will solicit and subaward up to 20 Ryan White HIV/AIDS Program (RWHAP)-funded recipients/subrecipients (approximately five sites per focus area) to serve as implementation sites where one (1) intervention strategy per site will be piloted. The piloted intervention strategies will be evaluated through the companion funding opportunity announcement titled *Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV – Evaluation Center* (2iS EC; HRSA- 21-068). Ultimately, the 2iS EC's evaluation findings will determine dissemination plans for the replication tools developed by the 2iS CCTA. Please review this companion announcement for more information about the role of the 2iS EC.

### 6. Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV – Evaluation Center – NEW!

<https://www.hrsa.gov/grants/find-funding/hrsa-21-076>

**MGH LOI Deadline: 2/01/21**

Sponsor Application Deadline: 3/08/21

This notice announces the opportunity to apply for fiscal year 2021 (FY21) Health Resources and Services Administration (HRSA) Special Projects of National Significance (SPNS) Program funding for the initiative *Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV – Evaluation Center*. The purpose of this initiative is to use an implementation science framework to evaluate the pilot testing of innovative intervention strategies in four (4) focus areas at implementation sites subawarded through the companion cooperative agreement *Using Innovative Intervention Strategies to Improve Health Outcomes among People with HIV – Coordinating Center* (2iS CCTA; HRSA-21-076), and to disseminate the evaluation findings. HRSA will fund one organization through a cooperative agreement for up to four (4) years to serve as the Innovative Intervention Strategies Evaluation Center (2iS EC). The 2iS EC will develop and carry out a multi-site evaluation that includes a customized site-specific evaluation for each of the up to twenty (20) implementation sites subawarded through the 2iS CCTA. In addition to the site-specific components, the evaluation will include cross-site components that are consistent across all subawardee sites. Throughout this initiative, the 2iS EC will work closely with the 2iS CCTA, which will provide technical assistance to the subawardees. Ultimately, the 2iS EC's evaluation findings will determine dissemination plans for the replication tools developed by the 2iS CCTA. Please review the companion funding opportunity announcement for more information on the role of the 2iS CCTA (HRSA-21-076).

### 7. Mentored Research Experiences for Genetic Counselors (R25)

<https://grants.nih.gov/grants/guide/pa-files/PA-21-074.html>

**MGH LOI Deadline: 3/02/21**

NIH LOI Deadline: 4/25/21

NIH Application Deadline: 5/25/21

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.

To accomplish the stated over-arching goal, this funding opportunity announcement (FOA) will support innovative educational activities with a primary focus on **Research Experiences**.

## Limited Submission Funding Opportunities – *updated 12/31/20*

### 8. Research Experience in Genomic Research for Data Scientists (R25)

<https://grants.nih.gov/grants/guide/pa-files/PA-21-075.html>

**MGH LOI Deadline: 3/02/21**

NIH LOI Deadline: 4/25/21

NIH Application Deadline: 5/25/21

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

To accomplish the stated over-arching goal, this funding opportunity announcement (FOA) will support creative educational activities with a primary focus on ***Research Experiences***.

### 9. New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (UG3/UH3 Clinical Trials Not Allowed)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-001.html>

**MGH LOI Deadline: 5/04/21**

NIH LOI Deadline: 6/08/21

NIH Application Deadline: 7/08/21

The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA will support intramural - extramural collaborations to develop additional physical modules that will enhance the platform's capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.